Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Prenetics Group ( (PRE) ) just unveiled an announcement.
On January 1, 2026, Prenetics Global Limited completed the sale of its third-party logistics distribution business operated by subsidiary Europa Sports Partners in an all-stock transaction valued at up to $13 million, as disclosed in a January 6, 2026 filing. The divestiture, which follows the $72 million sale of ACT Genomics in October 2025, is part of an ongoing portfolio optimization that concentrates capital and management attention on IM8, the company’s fastest-growing, highest-margin business line, with management highlighting an expected improvement in operating margins from the second quarter of 2026 as Prenetics exits roughly $6 million in annual operating losses tied to the non-core Europa unit. The transaction leaves fiscal 2025 results unchanged because the sale closed at the start of 2026, while Prenetics maintains a strong liquidity position of more than $70 million in cash and equivalents plus Bitcoin holdings and continues a strategic review of additional non-core assets, including its 35% stake in Insighta, with the stated objective of simplifying its structure and maximizing shareholder returns as IM8 scales globally.
The most recent analyst rating on (PRE) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page.
Spark’s Take on PRE Stock
According to Spark, TipRanks’ AI Analyst, PRE is a Neutral.
The overall stock score of 51 reflects significant profitability challenges and valuation concerns, despite positive technical trends. The company’s strong equity base and low leverage provide some financial stability, but improvements in cash flow and profitability are essential for a more favorable outlook.
To see Spark’s full report on PRE stock, click here.
More about Prenetics Group
Prenetics Global Limited (NASDAQ: PRE) is a health sciences company focused on consumer health and longevity through its flagship premium supplement brand IM8, co-founded with David Beckham and endorsed by top athletes such as Aryna Sabalenka. IM8 offers science-backed core nutrition products, including its NSF Certified for Sport Daily Ultimate Essentials powder supplement, and has rapidly scaled to more than $100 million in annual recurring revenue within 11 months of launch, targeting global consumers seeking holistic, high-end nutritional solutions.
Average Trading Volume: 151,973
Technical Sentiment Signal: Hold
Current Market Cap: $223.6M
For a thorough assessment of PRE stock, go to TipRanks’ Stock Analysis page.